



Published in final edited form as:

Am J Hypertens. 2012 November ; 25(11): 1188–1194. doi:10.1038/ajh.2012.106.

Paraoxonase 1 (*PON1*) C/T-108 Association With Longitudinal Mean Arterial Blood Pressure

Vibha Bhatnagar^{1,2}, Lin Liu¹, Caroline M. Nievergelt³, Erin Richard^{1,2}, Victoria H. Brophy⁴, Braj Pandey⁵, Michael S. Lipkowitz⁶, and Daniel T. O'Connor^{7,8}

¹Department of Family and Preventive Medicine, University of California San Diego, La Jolla, California, USA

²Department of Veterans Affairs, Health Services Research and Development, San Diego, California, USA

³Department of Psychiatry, University of California San Diego, La Jolla, California, USA

⁴Department of Human Genetics, Roche Molecular Systems, Pleasanton, California, USA

⁵Department of Veterans Affairs, General Internal Medicine, San Diego, California, USA

⁶Department of Nephrology and Hypertension, Georgetown University Medical Center, Washington, DC, USA

⁷Department of Medicine, University of California San Diego, La Jolla, California, USA

⁸Department of Pharmacology, University of California San Diego, La Jolla, California, USA

Abstract

Background—Blood pressure is a complex quantitative trait with a strong genetic component. In this study, we leveraged the Veterans Affairs electronic medical record system to explore the relationship between Paraoxonase 1 (*PON1*)-108 C/T (rs705379) and mean arterial blood pressure (MAP).

Methods—Outpatient blood pressure data over an approximate 8-year period was collected from the Veterans Affairs Hypertensive Cohort ($N = 1,302$). Association between genotype and longitudinal MAP was further explored using a random effects model controlling for age, ancestry, renal function, and other determinants of blood pressure. To control for population stratification, principal component groupings based on ancestry informative markers in this dataset were included as covariates (in addition to self-identified ancestry). Data from the African American Study of Kidney Disease and Hypertension (AASK, $N = 857$) was used to confirm significant findings in an independent cohort.

Results—There was a significant interaction between *PON1*-108 C/T genotype and follow-up age group. At a younger age (<50 years), there was an estimated 2.53 mm Hg (95% confidence interval: 1.06, 4.00) increase in MAP with each additional C-allele. At the older age groups, there were no significant associations between *PON1*-108 C/T genotype and MAP. Using data from the AASK trial, the C-allele at *PON1*-108 C/T was significantly associated with a higher MAP ($P = 0.005$) but only among younger participants (<54 years).

Conclusions—The *PON1*-108 polymorphism may be associated with MAP in an age-dependent manner.

Keywords

age; blood pressure; essential hypertension; hypertension; polymorphism; PON1; veterans

Hypertension is one of the most important risk factors for cardiovascular disease and renal failure in the United States. Blood pressure is a complex quantitative trait and varies with activity, lifestyle (salt intake, exercise, alcohol consumption etc.), comorbid medical disease, stress levels, and age. Although environmental and lifestyle factors play a crucial role in modulating the hypertensive phenotype, heritability estimates of hypertension are moderate to high, ranging from 20 to 55%.^{1–3} However, the contribution of a single genetic marker is likely to be limited because of the involvement of multiple gene variants, epigenetic interactions between genes and the environment and interactions between genes in several physiological pathways.

Paraoxonase 1 (*PON1*) is a serine esterase secreted by the liver, originally identified because of its role in the detoxification of paraoxon and other organophosphates.⁴ It is located on chromosome 7 and is a member of a gene family that includes *PON2* and *PON3*.⁵ *PON1* appears to be a significant physiological mediator of oxidative stress, modulating the release of pro-inflammatory enzymes resulting in atherosclerosis and subsequent plaque formation. It is associated with high-density lipoprotein and prevents oxidation of low-density lipoprotein.⁶ Homocysteine thiolactone, a highly reactive metabolite of homocysteine, is another endogenous substrate for *PON1*; some of the cardio-protective effects of *PON1* may be partially mediated through homocysteine thiolactone clearance.⁷ There is strong linkage disequilibrium across the *PON1* gene, and *PON1* activity has been shown to be up-regulated by the C-allele at –108 (rs705379).⁸ However, *PON1* activity is also heavily modulated by environmental factors with much individual variation independent of genotype.^{9,10}

Because of the association with atherosclerosis, we hypothesized that *PON1* variation may be associated with blood pressure. In this study, we leveraged the extensive Veterans Affairs (VA) electronic medical record system to systematically phenotype and collect outpatient blood pressure data over an average of 8 years from a multi-ethnic VA Hypertensive Cohort (VAHC)¹¹. The association between *PON1*-108 C/T genotypes and mean arterial blood pressure (MAP), a composite of systolic and diastolic blood pressure, was then modeled at follow-up age groups (<50 years, 50–70 years, and >70 years) controlling for determinants of hypertension.

Methods

Study population

Details of the multi-ethnic VAHC have been previously published.¹¹ Protocol approval and informed consent were obtained according to the requirements of the University of California San Diego Human Subjects Protection Program and the Research Committee of the San Diego VA Medical Center. Briefly, 1,527 participants from the VA San Diego Healthcare System were recruited to participate in a long-term follow-up study. Of these, 1,302 (89%) with phenotype and genetic data were included in this analysis.

The majority were men (96%) with an average age of 64.3 ± 12.7 years. As described in our previous work, participants were recruited either in clinic or by mail; clinic recruits were younger with higher blood pressures. Data was extracted from the regional Veterans Integrated System Network 22 from 1999 to December 2007; data included detailed

biomedical parameters (labs, vital signs, body mass index etc.) and medical diagnoses. Study participants had an average of 87.4 ± 22.9 months of follow-up per person and 47 (range: 1–582) outpatient blood pressure readings per person. In addition to using the electronic medical records, study participants completed a survey designed to query lifestyle parameters such as salt intake, tobacco, and alcohol intake.

Ancestry and population stratification

Participants were self-identified as European American ($N = 876$), African American ($N = 204$), Asian American ($N = 49$), Hispanic/Latino ($N = 78$), Native American ($N = 27$), or unidentified ($N = 68$). The main analysis focused on European and African Americans. Since there were few members in the other racial groupings, the remaining groups were collapsed, limiting the ability to interpret the results for this third group. In addition to self-identified ethnicity, 87 autosomal ancestry informative markers from our data set were used in a multi-dimensional scaling analysis using the PLINK routine (<http://pngu.mgh.harvard.edu/purcell/plink/>),¹² and the first four multi-dimensional scaling components were included as covariates to adjust for residual population stratification.

Genetics

As previously detailed, buccal cell DNA was collected at the time of recruitment and stored; 1,474 (~96.5%) buccal cell samples yielded good quality (polymerase chain reaction-amplifiable) DNA, with an average DNA yield of 5.02 ± 0.12 μg , by PicoGreen fluorescence (Invitrogen, Carlsbad, CA).¹¹ In this study, we focused on a promoter region polymorphism, –108 C/T on *PONI*.

Data analysis

Bivariate analysis—The bivariate associations between average MAP and other potential determinants of blood pressure were first explored. Associations between *PONI*-108 C/T genotypes and determinants of blood pressure were also explored. These determinants included other biomedical parameters such as serum creatinine, cholesterol and glycosolated hemoglobin A1C used to measure glucose control in patients with diabetes, medical diagnoses including type 2 diabetes, renal disease, cardiovascular disease, cardiac arrhythmias (including atrial and ventricular arrhythmias) and cerebrovascular disease, Charlson score (a composite measure of 17 comorbidities),^{13,14} and number of antihypertensive medications at recruitment. Lifestyle characteristics included perceived stress levels, salt intake, alcohol, and tobacco use.

Bivariate associations were tested using the Kruskal–Wallis test for continuous variables, and the χ^2 test or Fisher's exact test for categorical variables. Variables that were associated with either average MAP or genotype ($P < 0.15$) were considered as covariates in the longitudinal modeling analysis described below.

Longitudinal modeling of MAP—The association between *PONI*-108 C/T genotypes and longitudinal MAP (over an approximate 8 years per study participant) was further explored using a random effects model. Follow-up age was categorized as younger adult (<50 years), middle-aged adult (50–70 years) and older adult (>70 years). An *a priori* model was not specified for genotypes; continuous/additive, categorical, and dichotomous (dominant/recessive) models were considered. In addition, a genotype by follow-up age interaction was also included in the base model. Random intercept and random age effect were considered and the significance of random effect was assessed using the likelihood ratio test.

The association between each potential covariate and blood pressure was also assessed using a random effects model. If a variable was significantly associated (P value <0.15) with blood pressure in the random effects model and also significantly associated with genotype in the bivariate association analysis described above, the variable was included as a covariate in the multivariable random effects model. A backward model selection was then used to remove insignificant covariates from the multivariable model. The variable with the largest P value was removed at each step, and the models with and without this variable were compared using the likelihood ratio test. If the P value of the likelihood ratio test was >0.05 , the variable was removed from the model. Only variables with a P value <0.10 were kept in the final model.

Sensitivity analyses: generalized estimating equation and baseline MAP—

Since the generalized estimating equation (GEE) method estimates the variance through a working correlation matrix using a robust variance estimate, we repeated the final model using GEE with an exchangeable working correlation structure as an initial sensitivity analysis. Because we could only control for baseline antihypertensive medications, changes in medications may have been a confounder in the longitudinal analysis. Therefore, we also did an analysis with only baseline (first) blood pressure data.

Replication sample—Finally, data from the African American Study of Kidney Disease and Hypertension (AASK) was used to confirm significant associations from the main analysis. The AASK study randomized African American men and women with hypertensive nephrosclerosis to treatment with ramipril, metoprolol, or amlodipine.¹⁵ Of the 1,094 subjects enrolled in the original study, 857 were enrolled in a follow-up genomics study. Linear regression analysis was used to determine the association between genotype and baseline MAP, controlling for covariates such as renal function, age, gender, and medications. A backward selection was used, and covariates with a $P > 0.1$ were retained in the final model.

Results

Genotype associations with baseline parameters

Consistent with publically available databases, allele frequency differed by ancestry with T-allele frequencies of 0.50 and 0.16 in European and African Americans, respectively (Table 1; http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=705379). Those with a C/T genotype had the lowest high-density lipoprotein level ($P = 0.008$) and those with a T-allele had a higher prevalence of cardiac arrhythmia ($P = 0.0008$). The T-allele was also associated with a lower prevalence of hepatitis C ($P = 0.0007$), alcohol use ($P = 0.005$), and tobacco use ($P = 0.004$).

Longitudinal modeling of MAP

There were significant interactions between *PON1*-108 C/T (additive model) and MAP change between the younger and middle ($P = 0.006$), and between the younger and older ($P = 0.003$) age group (Table 2). Results suggested that the change in MAP from the younger to the middle or older age group was different depending on the number of C-alleles at *PON1*-108 C/T. In addition, a history of cardiac arrhythmia ($P < 0.0001$), hemoglobin A1C ($P = 0.0005$), method of recruitment ($P = 0.002$) and European American ancestry as compared with African American ancestry ($P = 0.01$) were also significantly associated with MAP change. A history of hepatitis C was marginally associated with MAP change ($P = 0.06$) and was retained in the final model.

Because of the interaction between *PONI*-108 C/T genotypes and follow-up age, the data was first stratified by age in order to estimate the effect of *PONI*-108 C/T genotype on MAP (Figure 1). At a younger age, MAP increased by 2.53 mm Hg (95% confidence intervals (CI): 1.06, 4.00) with each additional C-allele at *PONI*-108 (Table 3). In the middle and older ages, MAP did not significantly vary by *PONI*-108 genotypes (Table 3).

In order to estimate the effect of age on the change in MAP, the data was then stratified by *PONI*-108 genotypes (Table 4). The MAP at a middle age was significantly lower as compared with MAP at a younger age for individuals with two C-alleles. The estimated decrease in blood pressure was 3.23 mm Hg (95% CI: -4.85, -1.62). Significant decreases in MAP between older age and younger age were found for individuals with one or two C-alleles, with an estimated MAP decrease of 4.46 (95% CI: -5.58, -3.11) and 7.06 mm Hg (95% CI: -8.95, -5.17), respectively. Finally, there were significant decreases in blood pressure from middle to older age for all genotypes, with the greatest decrease among those with two C-alleles. Those with no C-alleles (T/T genotype) had a 2.90 mm Hg (95% CI: -4.31, -1.50) decrease, those with one C-allele (C/T genotype) had a 3.36 mm Hg (95% CI: -4.21, -2.52) decrease and those with two C-alleles had a 3.82 mm Hg (95% CI: -5.17, -2.48) decrease in MAP (Table 4 and Figure 1).

Sensitivity analyses: GEE and baseline blood pressure

Similar results were found using GEE (results not shown). Because changes in medications could have influenced blood pressure in the longitudinal analysis, the analysis was repeated with only baseline blood pressures. *PONI*-108 genotypes were significantly associated with MAP ($P=0.008$; results not shown). In comparison with the younger age group, the interaction terms between genotype and follow-up age were marginally significant for the middle age group ($P=0.053$) and for the older age group ($P=0.07$; results not shown). Similar to the longitudinal results, there was a 4.0 mm Hg increase in MAP (95% CI: 1.04, 7.0) with an additional C-allele in the younger age group. There was no difference in MAP in the middle and older age groups by *PONI*-108 genotypes. Among those with two C-alleles, MAP significantly decreased between the older and younger age groups by 5.22 mm Hg (95% CI: -9.50, -0.93).

Replication sample

Of the 857 AASK study participants, 791 were genotyped at *PONI* C/T-108. There was a significant interaction between genotype and median age ($P=0.02$). For study participants below the median age of 54, there were significant differences in baseline MAP by *PONI*-108 genotypes, with higher MAP observed among those with a C-allele ($P=0.005$). For study participants 54 years and older, baseline MAP did not significantly vary by *PONI* genotypes (Figure 2).

Discussion

Main results

In this study, we used the longitudinal VAHC with blood pressure data on 1,302 hypertensive patients collected over an approximate 8-year period to explore the association between MAP and *PONI*-108 C/T, a promoter region polymorphism (rs705379). Results suggested that there was an estimated 2.53 mm Hg increase in MAP with each additional C-allele at a younger age (<50 years). There was also a notable decrease in MAP with age among those with C/C genotype. A sensitivity analysis using on baseline blood pressure yielded similar results. Finally, in an independent cohort of 791 African Americans with early hypertensive nephrosclerosis, the *PONI*-108 C-allele was also associated with higher baseline MAP among the younger participants <54 years.

PON1, cardiovascular disease and hypertension

Although *PON1* genotypes have been most commonly studied in the context of association with atherosclerosis and cardiovascular disease,¹⁶ a large population based study suggested that *PON1* activity was inversely associated with the risk of cardiovascular disease, but not independently of high-density lipoprotein cholesterol.¹⁷ *PON1* 192 R has been associated with premature myocardial infarction,¹⁸ an 80% increased risk in coronary artery disease,¹⁹ number of diseased coronary vessels²⁰ and an over twofold increase of stroke.²¹ *PON1* 55 L is also associated with more advanced atherosclerosis.²²

In this study, the *PON1*-108 C-allele was associated with higher blood pressure among those in the younger (<50 years) age group, suggesting that the C-allele is a determinant of early onset hypertension. This may be especially important among African Americans and other ancestral groups who have a higher frequency of this allele. However, this association is somewhat counter-intuitive because the C-allele has been shown to result in higher *PON1* activity and is thought to be cardio-protective.⁸ Although we cannot be certain as to why we observed this association, the C-allele is also in linkage disequilibrium with L55M which has been associated with increased cardiac risk.^{8,20,22} *PON1*-108 C/T genotypes were not significantly associated with MAP at older follow-up age groups consistent with research suggesting that *PON1* activity decreases with age.²³

At a population level, blood pressure is known to steadily increase with age, and then decrease somewhat with advanced age²⁴. In this study, those with two C-alleles had a higher MAP at the younger age, with a clinically notable and significant decrease in MAP at middle and older age. At a population level one would expect an increase in blood pressure in the middle age group; however, it should be noted that how blood pressure changes with age and genetic stratification is unknown. In addition, comorbid disease and changes in medication could confound the longitudinal analysis. In order to address this, a sensitivity analysis using only baseline MAP yielded similar results for those with two C-alleles. In replication sample using AASK data, blood pressure did increase among those over the median age of 54 years. It should be noted that in comparison with VAHC, the AASK cohort had renal disease and was on average 10 years younger with a limited age range.

The association between *PON1*-108 C/T and MAP appears to be a somewhat novel finding. It is unknown whether *PON1* modulates blood pressure independent of accelerated atherosclerosis or whether other family members such as *PON2* located on smooth muscle cells may be contributing to blood pressure modulation. Although the C-allele has been shown to increase *PON1* levels, *PON1* is also up-regulated with the consumption of flavonoids, pomegranate, vitamin C, and the use of statins and down-regulated with high-fat diets, smoking and heavy alcohol consumption.²⁵⁻²⁷ Therefore, measured *PON1* activity levels and the influence of environmental modulators should be considered in future studies. With respect to veteran patient populations, the effect of environmental toxin exposure during active duty may be an important consideration. Although there were significant associations between *PON1*-108 C/T and with comorbid disease, these associations did not remain significant after controlling for age and ancestry, suggesting that confounding as a result of population substructure was an important consideration in this dataset (results not shown).

Study strengths and limitations

Because of the longitudinal nature of this dataset, we were able to uncover a novel association between a *PON1* polymorphism and blood pressure among the younger members of the VAHC cohort. In comparison with routine prepost blood pressure readings or measurements, we had a much more comprehensive sampling of outpatient

measurements. Since changes in medications could have confounded our results, a sensitivity analysis with only baseline blood pressures was done, yielding similar results. Finally, we used both self-identified as well as genetically determined ancestry in our analyses to control for population stratification.

Although the VAHC is limited to study volunteers recruited from General Internal Medicine, this cohort appears to be representative to the general VA hypertension population.¹¹ Residual confounding remains a concern especially in the study of complex medical traits. Whether selection or loss to follow-up biases the observed associations is unknown. This is also primarily a male veteran cohort, and whether these results can be extrapolated to other study populations remains to be studied. The limited number of Native Americans, Filipinos, and Latinos were grouped together; hence the findings here cannot be interpreted as specific to any one ancestral group. Finally, the effects of PON1 activity, diet and other environmental factors also remain to be explored.

Leveraging off the comprehensive VA electronic medical record system, we explored the association between *PON1*-108 C/T genotypes and longitudinal MAP over an approximate 8-year period. The C-allele at *PON1*-108 was associated with an estimated 2.53 mm Hg increase in MAP among younger adults (<50 years), with consistent findings in an independent cohort of African American men and women with hypertensive nephrosclerosis. This finding has both primary care and public health significance. *PON1*-108 genotypes may be an important determinant of hypertension among younger adults especially in ancestral patient populations such as African Americans who have a higher frequency of the *PON1*-108 C-allele. Study participants with the C-allele also had a notable decline in blood pressure with age, suggesting that careful attention to medication dosing may be important for these patients. Although it is premature to recommend genotype testing, further study of *PON1* and family members *PON2* and *PON3* in larger multi-ethnic studies with younger adults is warranted in order to further understand the effects *PON* gene family variation on blood pressure.

Acknowledgments


The funding sources for this study are: National Institutes of Health (K23 RR020822, HL58120, EXPORT/CRCHD MD000220, GCRC RR000827, 1R01MH093500-01), Department of Veterans Affairs.

References

1. Barlassina C, Lanzani C, Manunta P, Bianchi G. Genetics of essential hypertension: from families to genes. *J Am Soc Nephrol*. 2002; 13(Suppl 3):S155–S164. [PubMed: 12466306]
2. Levy D, DeStefano AL, Larson MG, O'Donnell CJ, Lifton RP, Gavras H, Cupples LA, Myers RH. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. *Hypertension*. 2000; 36:477–483. [PubMed: 11040222]
3. Ward, R. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh, JH.; Brenner, BM., editors. *Hypertension: Pathophysiology, Diagnosis and Management*. 2nd edn.. New York: Raven Press; 1995. p. 67-88.
4. Mackness MI. 'A'-esterases. Enzymes looking for a role? *Biochem Pharmacol*. 1989; 38:385–390. [PubMed: 2917004]
5. Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. *J Mol Med*. 2003; 81:766–779. [PubMed: 14551701]
6. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. *Atherosclerosis*. 1993; 104:129–135. [PubMed: 8141836]

7. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. *J Biol Chem.* 2000; 275:3957–3962. [PubMed: 10660550]
8. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. *Am J Hum Genet.* 2001; 68:1428–1436. [PubMed: 11335891]
9. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, Margolin S, Rieder M, Nickerson D, Schellenberg GD, Heagerty PJ, Furlong CE. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. *Arterioscler Thromb Vasc Biol.* 2003; 23:1465–1471. [PubMed: 12805074]
10. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, Furlong CE. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. *Arterioscler Thromb Vasc Biol.* 2000; 20:2441–2447. [PubMed: 11073850]
11. Salem RM, Pandey B, Richard E, Fung MM, Garcia EP, Brophy VH, Schork NJ, O'Connor DT, Bhatnagar V. The VA Hypertension Primary Care Longitudinal Cohort: Electronic medical records in the post-genomic era. *Health Informatics J.* 2010; 16:274–286. [PubMed: 21216807]
12. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet.* 2007; 81:559–575. [PubMed: 17701901]
13. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol.* 1992; 45:613–619. [PubMed: 1607900]
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987; 40:373–383. [PubMed: 3558716]
15. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER III, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S. African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. *JAMA.* 2001; 285:2719–2728. [PubMed: 11386927]
16. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. *Lancet.* 2004; 363:689–695. [PubMed: 15001326]
17. Birjmohun RS, Vergeer M, Stroes ES, Sandhu MS, Ricketts SL, Tanck MW, Wareham NJ, Jukema JW, Kastelein JJ, Khaw KT, Boekholdt SM. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study. *PLoS ONE.* 2009; 4:e6809. [PubMed: 19710913]
18. Gluba A, Pietrucha T, Banach M, Piotrowski G, Rysz J. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. *Angiology.* 2010; 61:157–165. [PubMed: 19939821]
19. Mendonça MI, Dos Reis RP, Freitas AI, Sousa AC, Pereira A, Faria P, Gomes S, Silva B, Santos N, Serrão M, Ornelas I, Freitas S, Araújo JJ, Brehm A, Cardoso AA. Human paraoxonase gene polymorphisms and coronary artery disease risk. *Rev Port Cardiol.* 2008; 27:1539–1555. [PubMed: 19280995]
20. Ozkök E, Aydin M, Babalik E, Ozbek Z, Ince N, Kara I. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients. *Med Sci Monit.* 2008; 14:CR536–CR542. [PubMed: 18830194]
21. Ranade K, Kirchgessner TG, Iakoubova OA, Devlin JJ, DelMonte T, Vishnupad P, Hui L, Tsuchihashi Z, Sacks FM, Sabatine MS, Braunwald E, White TJ, Shaw PM, Dracopoli NC. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. *Stroke.* 2005; 36:2346–2350. [PubMed: 16239632]

22. Malin R, Järvinen O, Sisto T, Koivula T, Lehtimäki T. Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis. *Atherosclerosis*. 2001; 157:301–307. [PubMed: 11472729]
23. Cherki M, Berrougui H, Isabelle M, Cloutier M, Koumbadinga GA, Khalil A. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging. *Exp Gerontol*. 2007; 42:815–824. [PubMed: 17532162]
24. Goldman, L.; Ausiello, D., editors. *Cecil Medicine*. 23rd edn.. Philadelphia, PA: Saunders; 2008. p. 120
25. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, Schellenberg GD, Heagerty PJ, Hatsukami TS, Furlong CE. Vitamin C and E intake is associated with increased paraoxonase activity. *Arterioscler Thromb Vasc Biol*. 2002; 22:1329–1333. [PubMed: 12171796]
26. Rao MN, Marmillot P, Gong M, Palmer DA, Seff LB, Strader DB, Lakshman MR. Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans. *Metab Clin Exp*. 2003; 52:1287–1294. [PubMed: 14564680]
27. Sutherland WH, Walker RJ, de Jong SA, van Rij AM, Phillips V, Walker HL. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. *Arterioscler Thromb Vasc Biol*. 1999; 19:1340–1347. [PubMed: 10323788]

Estimated MAP by follow-up age for *PON1***Figure 1.**

Estimated mean arterial blood pressure (MAP) at follow-up age by *PON1*-108 genotypes. Estimated MAP from the random effects model with covariate adjustment by the three age groups is shown. There was a 2.53 (1.06, 4.00) increase in MAP with each additional C-allele at a younger adult (<50 years) age group. There was no significant difference in MAP by *PON1*-108 genotypes at older follow-up age groups. MAP also significantly declined from the middle (50-70 years) to older adult age groups (>70 years), and this decline was most pronounced for those with *PON1*-108 C/C genotype. *PON1*, Paraoxonase 1.




Figure 2. Replication study from African American Study of Kidney Disease and Hypertension: distribution of baseline mean arterial blood pressure (MAP) by *PON1*-108 genotypes and age. In comparison to those with a C-allele, those with *PON1*-108 T/T genotype had a significantly lower baseline MAP among the younger (<54 years) study participants ($P=0.005$). *PON1*, Paraoxonase 1.

Table 1

Baseline characteristics by *PON1*-108 C/T genotypes

| | CC = 436 | CT = 583 | TT = 283 | <i>P</i> value ^a |
|--|--------------|--------------|--------------|-----------------------------|
| Demographics | | | | |
| Mean age (SD) | 61.7 (12.7) | 64.2 (12.4) | 66.9 (12.4) | <0.0001 |
| Male (%) | 413 (95%) | 557 (96%) | 275 (97%) | 0.28 |
| Self-identified ancestry | | | | <0.0001 |
| African American (%) | 142 (33%) | 58 (10%) | 4 (1%) | |
| Caucasian American (%) | 230 (53%) | 423 (73%) | 223 (79%) | |
| Other (%) | 64 (15%) | 102 (18%) | 56 (20%) | |
| Vital status (% still alive) | 392 (90%) | 506 (87%) | 249 (88%) | 0.31 |
| Recruited by mail (%) | 181 (42%) | 285 (49%) | 166 (59%) | <0.0001 |
| Mean baseline biochemical and anthropometric measures | | | | |
| Creatinine mg/dl (SD) | 1.3 (3.3) | 1.4 (6.4) | 1.0 (0.3) | 0.55 |
| Hemoglobin A1C mg/dl (SD) | 6.6 (1.6) | 6.5 (1.4) | 6.3 (1.2) | 0.13 |
| Glomerular filtration rate ml/min/1.73 m ² (SD) | 85.8 (28.4) | 82.9 (25.0) | 80.8 (23.2) | 0.02 |
| LDL cholesterol mg/dl (SD) | 114.7 (40.5) | 111.7 (33.8) | 111.4 (32.0) | 0.84 |
| HDL cholesterol mg/dl (SD) | 46.5 (13.9) | 44.3 (12.8) | 45.6 (15.3) | 0.008 |
| BMI kg/m ² (SD) | 29.7 (5.5) | 30.4 (5.9) | 30.3 (6.2) | 0.21 |
| Medical history | | | | |
| Type 2 diabetes (%) | 152 (35%) | 204 (35%) | 91 (32%) | 0.68 |
| Arrhythmias (%) | 46 (11%) | 79 (14%) | 58 (20%) | 0.0008 |
| Coronary artery disease (%) | 162 (37%) | 236 (41%) | 128 (45%) | 0.10 |
| Cerebrovascular disease (%) | 34 (8%) | 55 (9%) | 27 (10%) | 0.60 |
| Cancer (any history of cancer %) | 70 (16%) | 111 (19 %) | 59 (21%) | 0.24 |
| Kidney/renal disease (%) | 41 (9%) | 62 (11%) | 26 (9 %) | 0.73 |
| Hepatitis C (%) | 29 (7%) | 22 (4%) | 3 (1%) | 0.0007 |
| Psychiatric disorders (%) | 195 (45%) | 214 (37%) | 101 (36%) | 0.016 |
| Charlson score (SD) | 2.72 (3.1) | 2.93 (3.0) | 2.96 (2.9) | 0.16 |
| Number of medications (SD) | 2.4 (1.4) | 2.3 (1.4) | 2.3 (1.4) | 0.91 |
| Family history of hypertension (%) | | | | 0.47 |
| Yes | 255 (60%) | 343 (59%) | 151 (54%) | |
| No | 57 (13%) | 78 (14%) | 48 (17%) | |
| Lifestyle factors | | | | |
| Smoking status (%) | | | | 0.004 |
| Current | 96 (23%) | 114 (20%) | 42 (15%) | |
| Past | 208 (50%) | 308 (55%) | 181 (64%) | |
| Never | 115 (27%) | 143 (25%) | 57 (20%) | |
| Mean smoking in years (SD) | 14.6 (16.9) | 15.8 (17.4) | 16.7 (17.4) | 0.18 |

| | CC = 436 | CT = 583 | TT = 283 | <i>P</i> value ^a |
|------------------------------------|-----------|-----------|-----------|-----------------------------|
| Stress (%) | | | | 0.11 |
| Little to none | 79 (18%) | 110 (19%) | 61 (22%) | |
| Moderate | 234 (54%) | 311 (54%) | 167 (59%) | |
| High | 117 (27%) | 156 (27%) | 54 (19%) | |
| Caffeine (%) | | | | 0.45 |
| <2 caffeinated beverages/day | 239 (55%) | 305 (53%) | 136 (48%) | |
| 2–5 caffeinated beverages/day | 164 (38%) | 223 (39%) | 121 (43%) | |
| >5 caffeinated beverages/day | 31 (7%) | 45 (8%) | 26 (9%) | |
| Alcohol dependence (%) | 71 (16%) | 66 (11%) | 24 (8%) | 0.005 |
| Average number of drinks/week (SD) | 7.2 (5.8) | 7.4 (6.0) | 7.5 (6.1) | 0.95 |

^aComparison between genotype using Kruskal–Wallis test and the χ^2 or Fisher's exact test; *P* < 0.05 are given in bold.

BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein, *PON1*, Paraoxonase 1.

Table 2Estimated coefficients from random effects model for *PON1*

| | Coefficient | SE | P value |
|--|--------------------|-----------|----------------|
| Intercept | 101.60 | 1.66 | <0.0001 |
| Age (50–70 vs. <50 years) | 1.05 | 1.14 | 0.36 |
| Age (>70 versus < 50 years) | −1.86 | 1.22 | 0.13 |
| <i>PON1</i> genotype (number of C-alleles) | 2.53 | 0.75 | 0.0008 |
| History of arrhythmia | −2.66 | 0.63 | <0.0001 |
| History of hepatitis C | 2.08 | 1.10 | 0.06 |
| Hemoglobin A1C | −0.56 | 0.16 | 0.0005 |
| Clinic vs. mail recruitment | −1.52 | 0.47 | 0.002 |
| European American vs. African American | −1.77 | 0.71 | 0.01 |
| Others vs. African American | −0.33 | 0.83 | 0.69 |
| <i>PON1</i> by age (50–70 vs. <50 years) | −2.14 | 0.78 | 0.006 |
| <i>PON1</i> by age (>70 vs. <50 years) | −2.60 | 0.86 | 0.003 |

PON1, Paraoxonase 1.

Table 3Estimated MAP difference with *PONI* C-allele (95% confidence interval)

| Follow-up age | Estimated MAP change (95% confidence interval) |
|-----------------|--|
| <50 years old | 2.53 (1.06, 4.00) ^a |
| 50–70 years old | 0.39 (–0.43, 1.21) |
| >70 years old | –0.07 (–0.98, 0.84) |

Change in MAP with each additional C-allele at *PONI*.^aSignificant change in MAP.MAP, mean arterial blood pressure; *PONI*, Paraoxonase 1.

Table 4

Estimated MAP change by age (95% confidence interval)

| <i>PONI</i> genotype | Follow-up age (years) | | |
|----------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| | 50–70 vs. <50 | >70 vs. <50 | >70 vs. 50–70 |
| T/T (0 C-alleles) | 1.05 (–1.18, 3.27) | –1.86 (–4.25, 0.54) | –2.90 (–4.31, –1.50) ^a |
| C/T (1 C-allele) | –1.10 (–2.29, 0.10) | –4.46 (–5.81, –3.11) ^a | –3.36 (–4.21, –2.52) ^a |
| C/C (2 C-alleles) | –3.23 (–4.85, –1.62) ^a | –7.06 (–8.95, –5.17) ^a | –3.82 (–5.17, –2.48) ^a |

MAP, mean arterial blood pressure; *PONI*, Paraoxonase 1.^aSignificant change in MAP